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Bone and cartilage regeneration can be improved by designing a functionalized biomaterial that includes bioactive drugs in
a biocompatible and biodegradable scaffold. Based on our previous studies, we designed a vanadium-loaded collagen scaffold
for osteochondral tissue engineering. Collagen-vanadium loaded scaffolds were characterized by SEM, FTIR, and permeability
studies. Rat bone marrow progenitor cells were plated on collagen or vanadium-loaded membranes to evaluate differences in
cell attachment, growth and osteogenic or chondrocytic differentiation. The potential cytotoxicity of the scaffolds was assessed
by theMTT assay and by evaluation of morphological changes in cultured RAW 264.7 macrophages. Our results show that loading
of VOAsc did not alter the grooved ordered structure of the collagen membrane although it increased membrane permeability,
suggesting a more open structure. The VOAsc was released to the media, suggesting diffusion-controlled drug release. Vanadium-
loadedmembranes proved to be a better substratum than𝐶0 for all evaluated aspects of BMPC biocompatibility (adhesion, growth,
and osteoblastic and chondrocytic differentiation). In addition, there was no detectable effect of collagen or vanadium-loaded
scaffolds on macrophage viability or cytotoxicity. Based on these findings, we have developed a new ordered collagen scaffold
loaded with VOAsc that shows potential for osteochondral tissue engineering.
1. Introduction
Osteochondral damage is a frequent consequence of trau-
matic and degenerative alterations of joints and bones [1].
As articular cartilage is an avascular tissue in which dif-
ferentiated cells are embedded in an organic matrix, it
has a very limited potential for spontaneous healing [2,
3]. Different tissue engineering-based strategies have been
used to improve the regenerative capacity of osteochondral
lesions. In particular, a microfracture procedure combined
with scaffold implantation with or without the addition of
mesenchymal stem cells and/or growth factors has shown
promising results [4–7]. Filling the osteochondral defect
with an adequate matrix substitute (i.e., with functional
characteristics similar to those of the original tissue) can
decrease reparation time and thus patient morbidity [7–9].
The use of mesenchymal stem cells is of particular interest
since in response to specific factors they present the ability
to differentiate into osteoblasts or chondroblasts and since
they can be obtained from the same patient [10]. Despite
these encouraging aspects, an important number of patients
submitted to these procedures show worsening of their
lesions, underscoring the importance of perfecting the design
of an adequate biomaterial.
The inclusion of different bioactive molecules for bone
and/or cartilage regeneration has also been reported, leading
to the design of scaffolds that can function as a controlled
delivery system [11, 12]. This could improve the osteoinduc-
tive properties of the matrix and even reduce the cytotoxicity
of a certain drug, thus reducing the time required for tissue
repair. In addition, designing a functionalized or “intelligent”
biomaterial could optimize the degradation rate and dosifica-
tion of the bioactive molecule.
Although many materials have been developed for the
repair of osteochondral defects, none has equalled the
properties of collagen [13]. This natural polymer has been
Hindawi Publishing Corporation
International Journal of Biomaterials
Volume 2016, Article ID 1486350, 11 pages
http://dx.doi.org/10.1155/2016/1486350
2 International Journal of Biomaterials
used extensively because of its inherent biocompatibility,
biodegradability, osteoconductivity, and cost-effective avail-
ability [14]. Recently, we have prepared and characterized
a microscale ordered collagen scaffold and shown its effi-
cacy for bone tissue engineering [15]. Our results suggest
that the orientation of collagen fibers positively regulates
osteoblastic growth and development. When compared to
a randomly oriented collagen scaffold, the ordered collagen
matrix enhanced the in vitro osteogenic differentiation of
MC3T3E1 preosteoblasts increasing markers of osteoblast
differentiation and extracellular matrix mineralization [16].
In addition, we have previously reported the osteogenic
properties of a vanadyl(IV) ascorbate (VOAsc) complex as
well as its possible mechanisms of action, on two osteoblastic
cell lines in culture [17]. VOAsc significantly stimulated
osteoblastic proliferation and type I collagen production
and increased the formation of mineralization nodules. We
demonstrated that this complex inhibited several phos-
phatases, while simultaneously activating the ERK pathway
and regulating intracellular calcium levels and the PI3-
kinase pathway. Altogether our observations suggest that the
vanadium(IV) ascorbate complex could be a useful phar-
macological tool for bone tissue regeneration. On the other
hand,we have evaluated a delivery system for vanadiumusing
poly(𝛽-propiolactone) films [18]. In this system, vanadium
was liberated at a controlled rate causing a selective antipro-
liferative effect on osteosarcoma cells with lower cytotoxicity
than the drug in solution.
Based on our previous data, in the present work we
have designed an ordered collagen scaffold loaded with
different amounts of VOAsc and evaluated its potential use
for regeneration of bone and cartilage. We have determined
several physicochemical and biocompatibility properties of
the collagen scaffolds. In particular, we have investigated the
effects of VOAsc loaded into themembranes on the growth of
rat bone marrow progenitor cells (BMPC) and on their phe-
notypic differentiation into osteoblasts and chondroblasts.
We have also evaluated the possible in vitro cytotoxicity of
the scaffolds.
2. Materials and Methods
2.1. Membrane Preparation and Characterization. Mem-
branes were prepared using acid-soluble collagen extracted
from bovine Achilles tendon. Ordered films were obtained
according to standardized procedures of our laboratory
[15]. Vanadyl(IV) ascorbate (VOAsc) was synthesized as we
have previously described and characterized by UV-vis and
infrared spectroscopy [17, 19]. Stock solutions were prepared
in distilled water at room temperature and used immediately
for the different assays. Membranes of pure collagen were
loaded with the VOAsc complex and given an ordered
pattern by layering the collagen and vanadium solutions (50,
100, or 200𝜇g/mL) alternatively on a mold, according to
our previously described method [15]. This formulation was
selected in order to obtain 10, 20, or 40𝜇g/mLVOAsc per cm2
of membrane surface (𝐶1, 𝐶2, and 𝐶3). An ordered collagen
membrane without vanadium was also prepared as a control
(basal condition, 𝐶0).
Surface characteristics of the membranes were investi-
gated using scanning electron microscopy (SEM; Phillips
505, Netherlands), with an accelerating voltage of 25 kV.
The images were analyzed by Soft Imaging System ADDAII.
Fourier Transformed Infrared (FTIR) spectra were collected
to analyze and compare thematerial characteristics of all scaf-
fold samples following VOAsc addition. FTIR analysis was
carried out using an IRAffinity-1 SpectrumFTIR (Shimadzu).
Scaffolds were cut and fixed in a port-cell and spectra were
collected between 2000 and 800 cm−1.
Permeability was evaluated by measuring the flux of
NaCl across the membranes, with a custom-made glass cell
as previously described [15]. In this device the membrane
divides the cell in two compartments: one of them (𝐿) was
filled with the solution under study and the other (𝑅) with
distilled water. The complete cell was kept in a thermostatic
bath at 37∘C. The two half cells were stirred with a magnetic
device to avoid the possible formation of an unstirred layer
on the membrane surface. Fluid samples were taken from
compartment 𝑅 at regular intervals for conductivity deter-
mination of NaCl concentration with a Radiometer CMD3
conductivity meter. A calibration was previously performed.
Permeability is given by
𝑃 = 𝑉Δ(−
ln (1 − 2𝐶 (𝑡) /𝐶 (0))
2𝑎Δ𝑡
) , (1)
where 𝑉 is the cell volume, 𝑎 the membrane area, 𝐶(0)
the concentration of the solution at 𝑡 = 0, and 𝐶(𝑡) the
concentration at time 𝑡. A plot of ln(1 − 2𝐶(𝑡)/𝐶(0)) against 𝑡
was made using the determinations of 𝐶. After a least square
fit, the slope was taken as the value of 𝑃.
2.2. Vanadium Release Kinetic Studies. The release profile
of VOAsc from the scaffold was determined by incubating
scaffold samples (1 cm2) loaded with different amounts (10,
20, and 40 𝜇g/mL per cm2) of VOAsc in 1.0mL of sterile
DMEM without phenol red (pH = 7.4) at 37∘C for different
periods of time. At appropriate times (every 15min during
the initial hour, then every 30min until 5 h, and finally
every hour for 24 h), the supernatant was removed and
replaced by fresh media. The time-dependent release of the
drug was followed by monitoring the amount of VOAsc
present in the supernatant medium, using a T60 UV-visible
spectrophotometer (PG Instrument). A linear calibration
curve of VOAsc concentration versus absorbance at 580 nm
was obtained usingVOAsc standards in the range 0-1mg/mL.
The assay was performed in quadruplicate and results were
expressed as the fractional release (𝑀
𝑡
/𝑀
∞
) versus time of
release (𝑡).
2.3. Biocompatibility Studies
2.3.1. Cell Cultures and Incubations. The biocompatibility of
Col and Col-V (loaded with different amounts of VOAsc)
membranes was evaluated using rat bone marrow progenitor
cells (BMPC), investigating possible changes in their mor-
phology, growth, osteoblastic induction, and chondrogenic
differentiation when grown on the different scaffold. BMPC
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were chosen because they represent a better physiologic
model of osteogenesis due to its ability of self-renewal and
multilineage differentiation compared to cloned established
cell lines [20]. Under appropriate conditions, these cells
are able to differentiate into osteoblasts, chondroblasts, or
adipocytes. Additionally, they could also be used for in vivo
studies of bone tissue regeneration. BMPCwere isolated from
the femora of young male Sprague-Dawley rats and cultured
as previously described [21]. Cells were maintained in a
basal medium (DMEM-10% FBS) at 37∘C until being plated
on the different membranes, after which fresh medium was
added every 2 days. Prior to their use for cell culture, 1-2 cm2
scaffold samples were sterilized by immersion in 70% ethanol
and irradiation with UV light. After different incubation
periods, the 𝐶0 and Col-V vanadium-loaded membranes
were processed to evaluate cell adhesion, proliferation, or
differentiation.
In order to compare the direct effect of VOAsc addition
in the cell culture media with the effects of the com-
pound released from the membranes, some experiments
were performed with the BMPC plated on standard tissue
culture plates. In these cases, cells were incubated in a basal
mediumwith different doses ofVOAsc complex in solution as
indicated in Figures 1–7. After different incubation periods,
cell monolayers were processed to evaluate proliferation and
osteogenic differentiation as described below.
2.3.2. Evaluation of Cell Growth. The cells were washed
with phosphate-buffered saline (PBS, pH 7.4), after which
adherent cells were fixedwithmethanol, stainedwithGiemsa,
observed using a TS100 Eclipse Nikon microscope, and
photographed with a CCD camera with a 0.7x DXM Nikon
lens [16]. Cell adhesion (1 h after seeding) and proliferation
(24 h) were evaluated by counting the number of cells/field in
10 representative fields per experimental condition.
2.3.3. BMPC Differentiation. For BMPC osteoblastic dif-
ferentiation, cells were incubated for different periods of
time in osteogenic media (10% FBS-DMEM supplemented
with 5mM 𝛽-glycerol-phosphate and 25 𝜇g/mL ascorbic
acid). Osteogenic differentiation was evaluated by alkaline
phosphatase specific activity (ALP) and extracellular calcium
deposition (mineralization nodules). ForALPdetermination,
cells submitted to a 15-day osteogenic differentiation were
washed with PBS and solubilized in 0.5mL 0.1% Triton
X-100. Aliquots of this total cell extract were used for
protein determination [22] and for measurement of ALP
by spectrophotometric determination of the initial rates
(10min) of hydrolysis of p-nitrophenyl-phosphate to p-
nitrophenol at 37∘C. Mineralization nodules were measured
after 21 days of osteogenic differentiation using Alizarin S
red staining. Stained calcium deposits were extracted with
1mL of 0.1 N sodium hydroxide and the optical density
recorded at 548 nm. Additionally, type 1 collagen production
was evaluated in the cell monolayer plated into the standard
tissue culture plate to assess the effect of VOAsc in solution,
by Sirius red staining, as we previously described [17].
Chondrogenic differentiation was assessed after a
21-day culture in a chondrogenic medium [23]. Briefly,
107 BMPC/mL were resuspended in 40 𝜇L of serum-free
DMEM, and four individual drops (10 𝜇L per drop) were
carefully placed on Col or Col-V films included in each well
interior of 24-well plates. Cells were allowed to adhere at
37∘C for 2 h. Basal medium was then added for an additional
24 hours, after which it was replaced by a chondrogenic
medium (serum-free DMEM supplemented with 10 ng/mL
of TGF-b3 (PeproTech, USA), 10−8M dexamethasone,
and 1x insulin transferring selenium (ITS) supplement
(Invitrogen)), in which cells were cultured for 21 days
changing the medium every three days. Production of
chondroitin sulphate glycosaminoglycan (GAG), a marker
of chondrocytic differentiation, was evaluated by Alcian
blue staining (pH 3) at the end of the culture period. Briefly,
cells were fixed overnight and stained with 0.5% Alcian
blue in 0.1 N HCl, rinsed twice with 0.1 N HCl, and once
with distilled water. Finally, the dye was extracted with 4M
guanidinium HCl and absorbance was measured at 600 nm.
2.4. Evaluation of Scaffold Cytotoxicity. RAW 264.7
monocyte-macrophage cells were maintained in DMEM
containing 10% FBS, 100U/mL penicillin, and 100 𝜇g/mL
streptomycin at 37∘C in a 5% CO
2
atmosphere. This cell
line has previously been used in our laboratory to assess
cytotoxicity since it represents an adequate and sensitive in
vitro model for inflammation [16, 24]. After subculturing
with 10% EDTA, cells were seeded on either the Col or Col-V
membranes and incubated for 24 h after which the MTT
bioassay was performed. Briefly, 5mg/mL of MTT solution
was added and incubated for 3 h [24] until formation of
purple formazan crystals, which were dissolved in dimethyl
sulfoxide (DMSO) and absorbance measured at 490 nm. In
other experiments, morphology of RAW 264.7 cells cultured
on either scaffold was analyzed after Giemsa staining, using
a TS100 Eclipse Nikon microscope, and photographed with
a CCD camera with a 0.7x DXM Nikon lens.
2.5. Statistical Analysis. Results are expressed as the mean
± SEM and were obtained from at least three separate
experiments. Differences between the groups were assessed
by one-way ANOVA using the Tukey post hoc test. For
nonnormal distributed data, the nonparametrical Kruskal-
Wallis test with Dunn post hoc test was performed, using
GraphPad InStat, version 3.00 (GraphPad Software, San
Diego, CA, USA). 𝑝 < 0.05 was considered significant for
all statistical analyses.
3. Results
3.1. Membrane Characterization. Inclusion of vanadium in
the scaffold was demonstrated by FTIR spectra.The presence
of VOAsc in the collagen scaffold was evidenced by the
characteristics peaks for ascorbic acid at 1755 cm−1 (C=O
stretching) and 1670 cm−1 (C=C vibration) as has been pre-
viously described [19]. In the Col-V membrane spectra, both
a characteristic strong band of ](V=O) appearing at 962 cm−1
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Figure 1: Characterization of Col and Col-V scaffolds. FTIR spectra of Col, Col-V (20 𝜇g/mL per cm2 VOAsc) membrane, and the VOAsc
complex (a). SEM images of Col and Col-V surfaces ((b) and (c), resp.) showed an ordered matrix with a grooved structure. Transversal
section of Col and Col-V films ((d) and (e), resp.).
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Figure 2: NaCl flux experiments across Col-V (20𝜇g/mL per cm2
VOAsc) membrane at a temperature of 37∘C before (black) and after
(red) a 24 h wash of the membrane in distilled water.
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Figure 3: Fractional VOAsc drug release from the Col-V mem-
branes in vitro.𝐶1: 10 𝜇g/mL per cm2 VOAsc;𝐶2: 20 𝜇g/mL per cm2
VOAsc; and𝐶3: 40 𝜇g/mLper cm2VOAsc. Releasewasmeasured up
to 24 h. Insert: plot of log𝑀
𝑡
/𝑀
∞
versus log 𝑡 at initial times. Data
are presented as mean (𝑛 = 3).
and a peak at 1372 cm−1 corresponding to the (C3-O-)V
complex were observed. In addition, characteristic peaks
for collagen were evidenced at 1653 cm−1 (Amide I), 1550–
60 cm−1 (Amide II), and 1240 cm−1 (Amide III) (Figure 1(a)).
SEM analysis demonstrated a scaffold surface with par-
allel alignment of collagen fibers and a grooved structure
(Figure 1(b)), which was not influenced by the presence
of vanadium complex (Figure 1(c)). Superposition of the
collagen layers was homogeneous on both Col (Figure 1(d))
and Col-V (Figure 1(e)) scaffolds, revealing no influence
of vanadium complex on the morphology of the layers, as
observed by SEM. However, since SEM is not the most
sensitive method to evaluate alterations in pore structure of
the scaffold we also investigated the permeability properties
of the membranes.
Permeability is an important physicochemical charac-
teristic since VOAsc must be delivered from the scaffold
in order to act as an osteogenic compound. We measured
the flux of NaCl across the membrane as a measure of its
permeability at 37∘C.We found that the permeability value of
Col-Vmembrane was 2.16 × 10−4 cm/sec, which represents an
increase of about 40% compared to our previously described
values for Col scaffold (1.47 × 10−4 cm/sec [15]) (Figure 2).
We also evaluated the possible effect of VOAsc delivery
on scaffold permeability. Thus, permeability of Col-VOAsc
scaffolds was determined initially as described above and
again using the same membrane after 24 h of washing in
distilled water (Figure 2 red plot). We found an overlap
for both curves, indicating no differences in permeability
coefficient.
3.2. VOAsc Release Kinetics. In order to analyze the kinetics
of vanadium release, we used Fick’s second law for one-
dimensional transport in thin polymeric films with a mod-
erate swelling rate [25]:
𝑀
𝑡
𝑀
∞
= 𝑘𝑡
𝑛
, (2)
where𝑀
𝑡
is the cumulative absolute amount of drug released
at time 𝑡; 𝑀
∞
is the absolute cumulative amount of drug
profile released at infinite time; 𝑘 is a constant incorporating
structural and geometric characteristics of the device; and 𝑛
is the release exponent, indicative of the mechanism of drug
release. Figure 3 shows the fractional vanadium release from
𝐶1 to 𝐶3 films (containing different concentrations of the
drug) as a function of time. As it can be observed, the VOAsc
complex was released to the media in a controlled manner,
with a fast and linear kinetic during the first 3 h. At initial
rate a slight difference could be observed in theVOAsc release
for the different vanadium-loaded membranes. Nevertheless,
at the end of the incubation time, a saturation curve was
observed for each membrane with the release of vanadium
complex sustained for 24 h.The kinetics of such process could
be analyzed through the Fick model in order to determine
the 𝑛 exponent. The insert in Figure 3, a plot of log𝑀
𝑡
/𝑀
∞
versus log 𝑡, shows the linear regression plots of the fractional
vanadium release at short times. The diffusion coefficient
values (𝑛) were 0.425 ± 0.02, 0.374 ± 0.03, and 0.347 ± 0.02
for 𝐶1, 𝐶2, and 𝐶3, respectively, although not statistically
different. These results suggested that the mechanism of
vanadium release occurs by a Fickian diffusion process.
3.3. Effects of VOAsc on BMPC Proliferation and Differentia-
tion. In a first series of experiments, we used BMPC seeded
on standard tissue culture plates, in order to investigate the
effects of the VOAsc complex added directly into the culture
media. Treatment of cells with 2.5–100 𝜇M VOAsc for 24 h
led to a biphasic effect on cell proliferation. Figure 4(a)
shows that 10–50 𝜇M VOAsc significantly stimulated BMPC
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Figure 4: Effect of VOAsc on cell proliferation, differentiation, and mineralization. BMPC were incubated with different doses of VOAsc.
Cell proliferation was determined after 24 h of culture (a) and osteoblastic differentiation was assessed by ALP (b), type 1 collagen production
(c) and matrix mineralization by calcium nodules deposition (d) after 2 weeks of culture in an osteogenic media in the presence of different
concetrations of VOAsc. Data represent the mean ± SEM of three independent experiments and are expressed as % basal. ∗𝑝 < 0.05, ∗∗𝑝 <
0.01.
proliferation, while higher doses showed a tendency to inhibit
cell growth. The effect of vanadium complex on the BMPC
osteogenic potential was assessed after 2 weeks of culture in
osteogenic media, by determination of ALP, type 1 collagen
production, and nodules of mineral. As can be seen in
Figure 4(b), VOAsc did not affect ALP in BMPC. Under
similar conditions, VOAsc dose-dependently increases type
1 collagen production and calcium deposition in mineralized
nodules. These results indicate that, at low doses, VOAsc is
a weak mitogen and that its long term exposure to BMPC
results in osteogenic effects.
3.4. Biocompatibility of VOAsc-Collagen Scaffolds on BMPC.
Biocompatibility of the scaffolds was investigated using
BMPC. Cells were seeded on 𝐶0 and 𝐶1 to 𝐶3 scaffolds and
allowed to adhere (2 h) or growth (24 h). Cells attached to
both 𝐶0 and 𝐶2 membranes showed a random distribution
with homogeneous attachment between crests and valleys
(Figures 5(a) and 5(b), resp.). At higher magnification, cells
were either rounded or polyhedral with one ormore cytoplas-
mic extensions (Figures 5(c) and 5(d)). Similar results were
obtained for the other VOAsc-loadedmembranes,𝐶1 and𝐶3
(data not shown).
Then, we investigated the effect of loading different doses
of VOAsc on the collagen membranes in BMPC growth and
differentiation. As it can be seen in Figures 6(a) and 6(b)
there was a doses-dependent increase on both cell adhesion
and proliferation of BMPC compared to the ordered collagen
membrane (𝐶0). Cell differentiation was also improved in
the vanadium-loaded matrices. In those scaffolds, there was
a dose-dependent increase on ALP activity (Figure 6(c)) and
mineral deposits (Figure 6(d)) compared to collagen ordered
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Figure 5: BMPC attachment (2 h at 37∘C) to 𝐶0 ((a) and (c), Obj. ×10.) and 𝐶2 (20 𝜇g/mL per cm2 VOAsc) membranes ((b) and (d), Obj.
40x). Giemsa staining. Morphological images of BMPC are also representatives of the results for 𝐶1 and 𝐶3.
matrix (𝐶0). In addition, cells differentiated to chondrocytes
produced more GAG on 𝐶2 (20𝜇g/mL VOAsc per cm2)
scaffolds than on the 𝐶0 membranes (145 ± 11% of Col,
Figure 6(e)).
Thus, our observations suggest that the addition of a
growth factor such as the vanadium(IV) ascorbate complex
can improve the ability of a collagen matrix to support adhe-
sion, growth, and differentiation of BMPC to an osteoblastic
and chondrocytic phenotype.
3.5. Cytotoxicity Studies. Although collagen has been pre-
viously used for scaffold preparations and it demonstrated
being biocompatible, we wondered if our constructs might
generate any cytotoxic effect on cultures of RAW 264.7
macrophages. Figure 7(a) shows these cells’ growth well
on both the 𝐶0 and 𝐶2 scaffolds, maintaining their round
monocytic morphology without any signs of activation (i.e.,
absence of cytoplasm expansions such as spreading or for-
mation of cell protrusions). MTT evaluation demonstrated
the same number of surviving cells growing on 𝐶0 and 𝐶2
membrane (Figure 7(b)).
4. Discussion
Many strategies for bone tissue repair have focused on the
development of biomimetic scaffolds formulating innovative
tissue substitutes by the synergistic combination of matrices
with cell therapy. An interesting strategy is the combina-
tion of synthetic and natural polymers in order to achieve
suitable mechanical properties for bone tissue. Addition-
ally, improved osteoconductivity can be accomplished by
the incorporation into the scaffold of growth stimulating
substances and/or stem cells. Collagen is the principal com-
ponent of bone extracellular matrix and constitutes an inter-
esting material for bone tissue engineering since it provides
the innate biological information required for cell adhesion,
proliferation, and orientation and promotes a chemostatic
response [26]. On the other hand, collagen can be easily
oriented to obtain scaffolds with a micro- or nanometric
structure, which have been demonstrated to act as templates
for osteoblastic development [15, 16]. In this study, we have
extended our previous research to design a collagen-based
scaffold that incorporates a vanadium complex (VOAsc) with
in vitro osteogenic properties. Inclusion of VOAsc into the
collagen matrix did not influence the macrostructure of the
scaffold as observed by SEM, although it did increase the
permeability of the biomaterial. Interestingly, there was no
alteration in the permeability of vanadium-loaded scaffolds
before and after 24 h of washing, even when delivery exper-
iments demonstrated that VOAsc was positively released to
the media in the same period of time. Thus, we hypothesize
that the vanadium complex interacts reversibly with the
collagenous matrix creating a more permeable structure but
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Figure 6: Biocompatibility of BMPC on 𝐶0 and VOAsc-loaded scaffolds: 𝐶1: 10 𝜇g/mL per cm2 VOAsc; 𝐶2: 20 𝜇g/mL per cm2 VOAsc;
and 𝐶3: 40𝜇g/mL per cm2 VOAsc. Cells were plated on different collagen membranes and adhesion (1 h (a)) and proliferation (24 h (b))
were evaluated by Giemsa staining. Cells in 10 representative fields per sample were counted and averaged. BMPC growing on different
membranes were induced to be differentiated in osteogenic media: ALP (15 days (c)) or mineralization (21 days (d)) or chondrogenic media,
GAG production (21 days (e)). Results are expressed as % of basal (cells differentiated in the 𝐶0 film) and they are expressed as mean ± SEM.
∗𝑝 < 0.05; ∗∗𝑝 < 0.01; ∗∗∗𝑝 < 0.001.
does not lodge in the pores of the matrix. Permeability is a
physical parameter that describes complicated properties of
a material regulating various aspects of molecule transport
inside and outside the scaffold.This property is also an impor-
tant regulator of cell differentiation and scaffold degradation
[27–29]. Higher permeability values appear to be required
for osteogenic versus chondrogenic marker expression, an
effect correlating with the lower oxygen tension needed for
maintenance of chondrocytic phenotype [27]. In our culture
conditions, BMPC were able to grow and differentiate into
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Figure 7: Cytotoxicity studies with RAW 264.7 macrophages. (a)
Cells were cultured for 24 h on Col or Col-V (20𝜇g/mL per cm2
VOAsc) scaffolds, stained with Giemsa and photographed. (b) An
MTT assay was performed to evaluate cell survival of BMPC
growing on Col or Col-V scaffolds. Results represent the mean ±
SEM.
osteoblasts or chondrocytes on ordered collagen scaffolds,
expressing adequate levels of osteogenic or chondrocytic
markers when differentiated in lineage-specific conditions.
However, since both chondrogenic and osteogenic induc-
tion were significantly increased in the more permeable
vanadium-loaded scaffold, permeability does not seem to be
a primary regulator of cell fate in our system.
To date, several studies have evaluated bone and cartilage
regeneration using collagen scaffolds [5, 29, 30]. In these
studies, collagen constructs have been found to effectively
repair articular cartilage or bone defects. However some
unsolved problems remain, such as the need for periosteal
scaffold implantation to prevent detachment, articular sub-
stitution of hyaline cartilage by fibrocartilage, persisting pain,
and inadequate mechanical properties [5, 29–31]. In order to
improve the osteoinductivity of our ordered collagen matrix
we loaded it with the osteogenic complex VOAsc. We have
previously demonstrated that VOAsc in solution stimulates
osteoblastic growth and development, increasing collagen
secretion and extracellular mineralization in MC3T3E1 cells.
These effects correlated with an activation of the extracellular
regulated kinase (ERK) pathway [17]. We also shown that
VOAsc induces a fast ERK phosphorylation (minutes to
hours) and redistribution, suggesting that this complex could
regulate osteoblastic growth by MAPK pathways. In our
present study, we confirm previous observation of VOAsc
by using rat BMPC. BMPC are characterized by self-renewal
capacity and multilineage differentiation under specific cul-
ture conditions. Additionally it represents a better model of
bone cells, with the advantage that can be used in both in
vitro and in vivo studies for bone tissue regeneration. The
direct addition of VOAsc to the culture media stimulated
proliferation of BMPC growing on standard tissue culture
plates in a biphasic manner. Although low doses (10–50𝜇M)
significantly enhance cells growth, higher ones could be
inhibitory. In long term experiments, low doses of VOAsc
(5–25 𝜇M) significantly enhanced osteogenic potential of
BMPC, as indicated by osteoblastic markers type 1 collagen
production and matrix mineralization. More importantly,
these results suggest nontoxic effect of the vanadium complex
on these cells.
In our present system (BMPC grown on collagen scaf-
folds) it is to be expected that VOAsc must first be released
from the scaffold to exert cellular actions. Thus the release
kinetics was evaluated, showing a fast VOAsc release within
the first three hours of matrix immersion into the culture
media, after which the release reached a plateau. This effect
was shown not to be dependent on the concentration of
VOAsc loaded in the Col scaffold (Figure 3). Besides, the
evaluation of diffusion coefficient for the three membranes
studied was very similar suggesting that the rate of release
kinetic is mainly dependent on the diffusion process. Our
results could also be indicating that while an initial greater
release of VOAsc might benefit BMPC attachment and
growth, lower but sustained release of the vanadium complex
thereafter could be acting as an osteogenic or chondrogenic
agent. In this context, we found a stimulation of ALP activity
on cell growing on Col-V scaffolds in a dose-dependent
manner. The direct addition of VOAsc in the media did not
modify this marker. Alternatively, the initial interaction of
VOAsc present in the membrane with the cells could initiate
a signaling to induce specific transcriptor factors associated
with the fate of BMPC. Similar suggestions have been pro-
posed by Laurencin’s group by the short-term treatment of
small osteogenic molecules [32]. Local delivery has emerged
as an alternative to systemic delivery as it can avoid adverse
drug effects. In this sense other groups have developed
controlled-release systems directed to bone tissue, finding
both a decrease in drug toxicity and an increase in bone and
cartilage matrix deposition [33–35]. Indeed, inclusion of an
osteogenic drug in the scaffoldwould be expected to diminish
repair time [12].
Another important matter of concern is the possibility
that the implantable scaffolds may cause toxicity, inflam-
mation, or immunogenicity. For this reason we performed
experiments to evaluate the response of a macrophage cell
line in culture, RAW 264.7 cells, which is an accepted model
to study inflammatory response and cytotoxicity of drugs
or scaffolds. We have previously demonstrated that some
vanadium complexes directly added to culture media can
cause toxic effects such as an increase in reactive oxygen
and nitrogen species [36, 37]. In addition, oral treatments
with some vanadium derivatives have shown gastrointestinal
toxicity [38]. In this work, our results demonstrated that there
10 International Journal of Biomaterials
were no morphological changes in cells growing on either
collagen or vanadium-loaded collagen scaffolds. Moreover,
cells conserved the same proliferation rate on both kinds of
membranes. Thus, toxicity was avoided when vanadium was
included in the scaffold, a strategy that has been used by other
groups for cytotoxic drugs [34, 39, 40]. Although in certain
cases toxicity has been associated with scaffold degradation
[38–40], in our present system degradation of the collagen
scaffold with or without VOAsc, if it exists, does not appear
to cause toxicity.
5. Conclusion
In conclusion, we have developed ordered collagen scaffolds
for bone and cartilage tissue regeneration. VOAsc inclusion
into the scaffolds effectively promoted differentiation of
BMPC to osteoblasts and chondrocytes, without toxic effects.
Our results indicate that the collagen-VOAsc construct could
be of potential use in osteochondral tissue engineering.
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